P0070Improvement in quality of life in inflammatory bowel disease patients treated with advanced therapies: Interim findings from IBD-RESPONSE

Abstract Background Crohn’s disease (CD) and ulcerative colitis (UC) are typically characterised by diarrhoea, rectal bleeding, abdominal pain, and weight loss. In addition, patients often experience fatigue, joint pain and psychological distress (1). These symptoms can profoundly affect quality of life, and assessment of this is often underrepresented in clinical research. IBD-RESPONSE is a UK-wide multi-centre observational study aiming to develop a predictive algorithm for response to advanced therapies, utilising multi-omics data and extensive clinical metadata (2). Methods In IBD-RESPONSE, patient-reported outcome measures (PROMs) were collected at baseline and week 14. PRO-2 was used to calculate clinical response and remission (2). EQ-5D-5L was used to assess health-related quality of life across five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) from which a utility score was derived, alongside a Visual Analogue Scale (VAS) for perceived health status (3). In this interim analysis of 526 participants, we evaluated changes in quality of life between patients demonstrating treatment response, remission and non-response 14 weeks after commencing an advanced therapy using the Wilcoxon signed-rank test. Results EQ-5D-5L utility scores increased significantly overall, from 0.750 at baseline to 0.854 at week 14 (p 0.001). Utility scores improved in treatment responders (median change IQR = 0.1 0.042-0.202; p 0.001) and patients in remission (median change IQR = 0.096 0 – 0.195; p 0.001) but did not significantly improve in non-responders (median change IQR = 0.036 -0.085 – 0.120; p = 0.076). Similarly, overall VAS scores improved from 50 to 70 (p 0.001), with a significant increase among responders (median change IQR = 19 4.5-28; p 0.001) and for patients in remission (median change IQR = 20 6.5-35; p 0.001), but not among non-responders (median change IQR = 1 -10-17; P = 0.22). Conclusion Treatment response in IBD is associated with meaningful improvements in health-related quality of life. These findings highlight that better disease control not only reduces symptoms but also translates to an improvement in patient wellbeing. References: 1)Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Vol. 68, Gut. NLM (Medline); 2019. p. s1–106. 2. 2)Wyatt NJ, Watson H, Anderson CA, Kennedy NA, Raine T, Ahmad T, et al. Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine. BMJ Open. 2024 Apr 17;14(4). 3. 3)Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics (United Kingdom). 2018;27(1). Conflict of interest: Dr. Watson, Hannah: No conflict of interest Beck, Lauren: No conflict of interest Young, Greg: No conflict of interest Wyatt, Nicola: N/A Ahmad, Tariq: No conflict of interest Allerton, Dean: No conflict of interest Bates, Georgina: No conflict of interest Buckley, Amy: No conflict of interest Collins, Sonya: No conflict of interest Dong, Chaonan: No conflict of interest Doona, Mary: No conflict of interest Doyle, Jennifer: No conflict of interest Fachal, Laura: No conflict of interest Harris, Bradley: Personal Fees: I have received honoraria for a presentation at a BridgeBio board meeting. Hart, Ailsa: Grant: Takeda Personal Fees: Abbvie, Amgen, Arena, AZ, Falk, Celltrion, Eli Lilly, Ferring, Genentech/ Roche, GSK, Pfizer, Takeda, Napp, Pharmacosmos, Janssen (J & J), Bristol-Myers Squibb, Gilead, Galapagos, Alfasigma Hildreth, Victoria: No conflict of interest Hildreth, Victoria: No conflict of interest Irving, Peter Miles: Grant: MSD, Pfizer, Takeda, Celltrion, Galapagos Personal Fees: AbbVie, Arena, BMS, Boomerang Medical, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Sapphire Medical, Sandoz, Shire, Takeda, Tillotts, Topivert, VH2, Vifor Pharma, Warner Chilcott Jacques, Katherine: No conflict of interest Jostins-Dean, Luke: No conflict of interest Kennedy, Nicholas Alexander: Grant: Dr Kennedy’s department has received research funding from AbbVie, Biogen, Celgene, Celtrion, Galapagos, MSD, Napp, Pfizer, Pharmacosmos, Roche and Takeda Personal Fees: Dr Kennedy has served as a speaker and/or advisory board member for AbbVie, Amgen, BMS, Falk, Ferring, Galapagos, Janssen, Mylan, Pharmacosmos, Sandoz, Takeda and Tillotts Non-financial Support: Dr Kennedy has had support to attend meetings from AbbVie, Falk, Janssen and Tillotts Khan, Uzma: No conflict of interest Lees, Robert: No conflict of interest Liddle, Trevor: No conflict of interest Lees, Charlie: Consultancy and lecture fees: Abbvie, Oshi Health, Gilead, Pfizer, Takeda, Janssen, Shire, Samsung Bioepis, Dr Falk, GSK, Galapagos, Trellus Health, Iterative Scopes, Fresnius Kabi Lindsay, James: Investigator Initiated Research Grant: Takeda, Abbvie, Gilead Personal Fees: I have received fees for speaking and may have received support to attend academic conferences from: Abbvie UK/Global, Bristol Myers Squib, Cornerstones US, Gilead, Galapagos, Lilly, MSD UK, Ferring UK, Ferring Intl., Celltrion, Takeda, Pfizer, Janssen, Tillotts, Other: I serve of the advisory board of Abbvie UK/Global, Alpini, Astra Zeneca, Engytix, Galapagos, Gilead, GSK, Lily, MSD, Ferring UK, Ferring Intl., Celltrion, Takeda, Pfizer, Janssen, Shattucks Laboratory, Marchesi, Julian: No conflict of interest Martin, Cristina Cotobal: No conflict of interest McGregor, Naomi: No conflict of interest Mulligan, Robert: Robert J. Mulligan acknowledges research support from Open Targets, Wellcome Trust, European Bioinformatics Institute (EMBL-EBI), Genentech, GlaxoSmithKline, Merck Sharp and Dohme, Pfizer, and Sanofi and support for educational meeting attendance from Ferring. Parkes, Miles: Grant: Gilead, Pfizer, AstraZeneca, Galapagos, Lilly, Takeda Prescott, Natalie: No conflict of interest Powell, Nick: Grant: Takeda, BMS, Pfizer, Astra-Zeneca Personal Fees: Abbvie, Abivax, Allergan, Astra-Zeneca, Bristol-Myers Squibb, Celgene, Celltrion, Dr Falk Pharma UK Ltd, Ferring, Galapagos, GSK, Janssen, MSD, Roche, Pfizer, Sobi, Takeda, Tillotts Raine, Timothy: Grant: Abbvie, Takeda Personal Fees: TR has received research/educational grants and/or speaker/consultation fees from Abbvie, Alfasigma, Arena, Aslan, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Domain Therapeutics, Eli Lilly, Ferring, Galapagos, Gilead, GSK, Heptares, LabGenius, Janssen, MonteRosa, Mylan, MSD, Novartis, Numab, Pfizer, Roche, Sandoz, Scientia, Takeda, UCB and XAP therapeutics Satsangi, Jack: Grant: Grants to Oxford University from Helmsley Trust & European Community. Speight, Ally: Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AbbVie, Lilly, Dr Falk Pharma Janssen Support for attending meetings and/or travel: AbbVie, Dr Falk Pharma Janssen, Tillott’s pharmaceuticals Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: BSG IBD Section Committee (unpaid) Stewart, Christopher: No conflict of interest Strickland, Michelle: No conflict of interest Wood, Ruth: No conflict of interest Lamb, Christoph